Eprontia generic
Eprontia is an anti-epileptic drug owned by Azurity. It contains the active ingredient topiramate and was first authorized for market use on 5th November, 2021. The drug, available in an oral solution form, currently holds 2 patents, none of which have yet expired.
When will Eprontia generic be available?
The first generics of Eprontia are expected to become available after 21st August, 2040. This is determined by the expiry of Azurity's last patent (US11633374), which is valid until that date. Furthermore, another significant patent (US11433046) also expires on the same day.
Eprontia uses
Eprontia is indicated for various uses revolving around the treatment of seizures. It is used as adjunctive therapy for treating partial-onset seizures, primary generalized tonic-clonic seizures, and seizures related to Lennox-Gastaut syndrome in patients aged 2 years and above. Moreover, Eprontia is an approved initial monotherapy for treating partial-onset or primary generalized tonic-clonic seizures in patients of the same age range. The drug is also effective for the preventive treatment of migraine in patients aged 12 years and older. The effectiveness of Eprontia can be attributed to its active ingredient, topiramate.
Eprontia patent expiration
Two crucial patents safeguard Eprontia from generic competition until 21st August, 2040. The patents, US11633374 and US11433046, both concern the compositions and methods for treating epilepsy, seizures, and other conditions. These form the basis of Eprontia's protected status and influence the Eprontia generic release date. Below are the details of the patents: